Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Monday 01 October, 2018

AstraZeneca PLC

Atacand Agreement with Cheplapharm Completed

RNS Number : 4336C
AstraZeneca PLC
01 October 2018
 

1 October 2018 07:00 BST

 

Agreement with Cheplapharm for rights to
Atacand in 28 European countries completed

 

AstraZeneca has completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe.

Under the terms of the agreement, AstraZeneca has received a payment of $200 million from Cheplapharm. A time-bound payment of $10 million as well as sales-contingent milestones will also be payable. The present value of the upfront and time-bound payments will be reported as Other Operating Income in the company's financial statements in the third quarter of 2018.

AstraZeneca will continue to manufacture and supply Atacand and Atacand Plus under a supply agreement and will continue to commercialise the medicines in all markets where it still holds the rights.

About Atacand

Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. Atacand is also available in Europe as a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide (Atacand Plus). Atacand is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults. Atacand Plus is indicated for the management of hypertension when monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda. Each company holds the exclusive rights to the product in certain markets. In other markets, Atacand is co-marketed by both parties.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations



Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Gonzalo Viña

UK/Global

+44 203 749 5916

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Cardiovascular; Metabolism

+44 203 749 5711

Nick Stone

Respiratory; Renal

+44 203 749 5716

Josie Afolabi

Other

+44 203 749 5631

Craig Marks

Finance; Fixed Income

+44 7881 615 764

Jennifer Kretzmann

Retail Investors

+44 203 749 5824

US toll-free


+1 866 381 7277




Adrian Kemp

Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGREAENEDDXPEAF

a d v e r t i s e m e n t